Literature DB >> 2522783

Reduced numbers of complement receptor type 1 on erythrocytes are associated with increased levels of anticardiolipin antibodies. Findings in patients with systemic lupus erythematosus and the antiphospholipid syndrome.

A Hammond1, A C Rudge, S Loizou, S J Bowcock, M J Walport.   

Abstract

In several diseases, including systemic lupus erythematosus (SLE) and autoimmune hemolytic anemias, the numbers of complement receptor type 1 (CR1) expressed on erythrocytes of patients are reduced. In patients with SLE, anticardiolipin antibodies (aCL) have been associated with positive results on direct antiglobulin tests. Because of these findings, we investigated whether the reduced expression of erythrocyte CR1 in 61 patients (53 with SLE and 8 with the antiphospholipid syndrome) might be associated with the presence of aCL. A negative correlation was observed between aCL levels and mean numbers of CR1 (rs = -0.43, P = 0.001), and a positive correlation was observed between aCL levels and the levels of erythrocyte C4d and C3d (rs = 0.33 and 0.41, P = 0.01 and 0.001, respectively), but no correlation of aCL levels with serum C4 levels was found. When the results were further analyzed according to the IgG or IgM class of aCL, levels of antibodies of both classes were negatively correlated with CR1 numbers, but only IgM aCL levels were correlated with erythrocyte C4d and C3d numbers. The levels of anti-double-stranded DNA antibodies showed no correlation with erythrocyte CR1, C4d, or C3d numbers but were negatively correlated with serum C4 levels (rs = -0.43, P = 0.002). These data suggest that aCL, or a closely related antibody specificity, may bind to erythrocytes and may be directly involved in the mechanism for reduction of erythrocyte CR1 expression in SLE patients.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2522783     DOI: 10.1002/anr.1780320305

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  8 in total

1.  Clinical analysis of primary Sjögren's syndrome complicating anemia.

Authors:  Jing-Guo Zhou; Yu-Feng Qing; Li Jiang; Qi-Bin Yang; Wen-Feng Luo
Journal:  Clin Rheumatol       Date:  2010-02-20       Impact factor: 2.980

2.  Anaemia in systemic lupus erythematosus: aetiological profile and the role of erythropoietin.

Authors:  M Voulgarelis; S I Kokori; J P Ioannidis; A G Tzioufas; D Kyriaki; H M Moutsopoulos
Journal:  Ann Rheum Dis       Date:  2000-03       Impact factor: 19.103

3.  Effects of C4 null alleles and homoduplications on quantitative expression of C4A and C4B.

Authors:  A Hammond; W Ollier; M J Walport
Journal:  Clin Exp Immunol       Date:  1992-04       Impact factor: 4.330

4.  Evaluation of in vivo immune complex formation and complement activation in patients receiving intravenous streptokinase.

Authors:  J Freysdottir; S Ormarsdottir; A Sigfusson
Journal:  Clin Exp Immunol       Date:  1993-11       Impact factor: 4.330

Review 5.  Complement deficiency and immune complex disease.

Authors:  K A Davies; J A Schifferli; M J Walport
Journal:  Springer Semin Immunopathol       Date:  1994

6.  Reactivity patterns of anti-phospholipid antibodies in systemic lupus erythematosus sera in relation to erythrocyte binding and complement activation.

Authors:  J Arvieux; B Roussel; D Ponard; M G Colomb
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

Review 7.  Role of complement in antiphospholipid antibody-mediated thrombosis.

Authors:  Kathleen M O'Neil
Journal:  Curr Rheumatol Rep       Date:  2007-06       Impact factor: 4.686

Review 8.  Complement and systemic lupus erythematosus.

Authors:  Mark J Walport
Journal:  Arthritis Res       Date:  2002-05-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.